Actym Therapeutics is developing key biotech to help target intractable immune pathways in the tumor microenvironment.
Location: United States
Employees: 11-50
Total raised: $93.5M
Founded date: 2017
Investors 3
Funding Rounds 2
| Date | Series | Amount | Investors |
| 18.10.2023 | Series A | $59.5M | - |
| 27.04.2020 | Series A | $34M | - |
Mentions in press and media 8
| Date | Title | Description |
| 18.10.2023 | Actym Raises $59.5M In Series A funding | Actym Therapeutics, a Berkeley, CA-based provider of a new drug modality to treat solid tumors, raised $59.5M in Series A funding. The round was led by Boehringer Ingelheim Venture Fund and Illumina Ventures, with GKCC LLC as a new investor... |
| 11.11.2021 | Actym Therapeutics Appoints Chan Whiting as Chief Development Officer | BERKELEY, Calif., Nov. 11, 2021 /PRNewswire/ -- Actym Therapeutics, Inc. today announced the appointment of Chan Whiting, Ph.D. as Chief Development Officer. Chan brings over 20 years of drug development experience within the biotechnology ... |
| 13.01.2021 | Actym Therapeutics Announces Expansion of Scientific Advisory Board | BERKELEY, Calif., Jan. 13, 2021 /PRNewswire/ -- Actym Therapeutics Inc., a privately-held company focused on the development of immunotherapies to treat cancer from its attenuated, microbial-based STACT platform, announced today the appoint... |
| 28.04.2020 | Daily funding roundup - April 27th, 2020 | Auditoria.AI landed $6M; Codota secured $12M; Brain Corp raised $36M BuyMed: BuyMed is an online pharma marketplace. BuyMed raised $2.5 million from Sequoia Capital India and Genesia Ventures. Read more Tinvio: Tinvio is an order managing p... |
| 27.04.2020 | Actym Therapeutics Raises $34M Series A | BERKELEY, CA, Actym Therapeutics has announced the completion of a $34M series A financing led by Boehringer Ingelheim Venture Fund and Panacea Venture. >> Click here for more funding data on Actym Therapeutics >> To export ... |
| 27.04.2020 | Boehringer Ingelheim VC backs plan to send GMO bacteria after tumors | Chris Thanos wants to send bacteria after your tumors. Specifically, he wants to send salmonella after your tumors, a genetically modified form of the microbe that he and his team have neutered and retrofitted with gen... |
| 27.04.2020 | Actym Therapeutics Raises $34M in Series A Funding | Actym Therapeutics, a Berkeley, Calif.-based immuno-oncology company, completed a $34m series A financing. The round was led by Boehringer Ingelheim Venture Fund (BIVF) and Panacea Venture, with participation from Illumina Ventures, Korea I... |
| - | Actym | “Targeting Intractable Pathways in the TME” |